Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital

Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic.

Lei Wang is the lead UCSF inventor.